Protein / target

Vimentin

Encoded byVIMP08670Homo sapiensSwiss-Prot

UniProt: P08670 Ensembl: ENSG00000026025 HGNC: HGNC:12692 NCBI Gene: 7431

Clinical-stage

Therapeutic maturity

Clinical candidates

Small-molecule tractable

Druggability

High-Quality Pocket

Research papers

Protein at a glance

Biological role

Structural constituent of cytoskeleton

Strongest disease association

Early-onset non-syndromic cataract

Via encoding gene VIM · Genetic literature evidence · score 0.61

Therapeutic position

Clinically advancing target

Antibodies

Research activity

Emerging research

1 papers · latest 1999

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells.

View complete UniProt function annotation

Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally. Plays a role in cell directional movement, orientation, cell sheet organization and Golgi complex polarization at the cell migration front (By similarity). Protects SCRIB from proteasomal degradation and facilitates its localization to intermediate filaments in a cell contact-mediated manner (By similarity). May promote axon outgrowth and motor fiber repair via DSP-mediated recruitment to outgrowth tips (By similarity)

Subcellular location

CytoplasmCytoplasm, cytoskeletonNucleus matrixCell membraneCell projection, axon

Domains and Gene Ontology detail (29)

Domains & features

IF rod

Gene Ontology

Caxon
Ccell leading edge
Ccytoplasm
Ccytoskeleton
Ccytosol
Cextracellular exosome
Cfocal adhesion
Cintermediate filament
Cintermediate filament cytoskeleton
Cmicrotubule organizing center
Cnuclear matrix
Cperoxisome

466 aa · 54 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationUniProt

View supporting evidence

Cell migration

·Vimentins are class-III intermediate filaments found in various non-epithelial cells, es…

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene VIM

Gene-level evidence surfaced through the gene VIMthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Cataract

0.49Limited support

Genetic literature evidence dominant · Open Targets 0.37

Early-onset non-syndromic cataract

0.49Limited support

Genetic literature evidence dominant · Open Targets 0.46

Dengue

0.34Preliminary

Pathway evidence dominant · Open Targets 0.51 · no direct causal or clinical evidence

Hypertension

0.32Limited support

Genetic evidence dominant · Open Targets 0.19

Glioma

0.21Preliminary

Literature evidence dominant · Open Targets 0.12

View evidence synthesis (5)

CataractLimited support

0.49

agreement 0.34–0.65

Genetic literature97%Literature3%

Open Targets aggregate 0.37 · 2 independent evidence families

Early-onset non-syndromic cataractLimited support

0.49

agreement 0.34–0.64

Genetic literature99%Literature1%

Open Targets aggregate 0.46 · 2 independent evidence families

DenguePreliminary

0.34

agreement 0.16–0.52

Pathway97%Literature3%

Open Targets aggregate 0.51 · 2 independent evidence families · no direct causal or clinical evidence

HypertensionLimited support

0.32

agreement 0.18–0.46

Genetic96%Literature4%

Open Targets aggregate 0.19 · 2 independent evidence families

GliomaPreliminary

0.21

agreement 0.06–0.37

Literature54%Clinical46%

Open Targets aggregate 0.12 · 2 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Dengue0.51

Early-onset non-syndromic cataract0.46

Cataract0.37

Hypertension0.19

Glioma0.12

Neoplasms0.12

Drug development

1 compounds recorded · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (1)

PRITUMUMABPhase 2

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small molecules — Emerging

Feasibility evidence (high-quality pocket) — no clinical-stage drug of this modality recorded.

Antibodies — Strong

Advanced Clinical and UniProt loc med conf support this modality.

Protein degraders — Emerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (7)

SM · High-Quality PocketAB · Advanced ClinicalAB · UniProt loc med confAB · GO CC med confPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 1999

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium.1,153 cites

Olumi AF · Cancer research · 1999

Recent

Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium.

Olumi AF · Cancer research · 1999

Europe PMC papers linked directly to this protein.